Citius Pharmaceuticals Inc vs GE Vernova Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while GE Vernova Inc trades at $1,042 (market cap $269.50B). The key difference: GE Vernova Inc is far larger — about 13468.3× Citius Pharmaceuticals Inc's market cap, and GE Vernova Inc pays a 0.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GEV | |
|---|---|---|
Market Cap | $20.01M | $269.50B |
Sector | Health | Technology |
52-Week High | $1.82 | $1.17K |
52-Week Low | $0.48 | $547.96 |
Enterprise Value | $16.23M | $259.17B |
Dividend Yield | — | 0.2% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
GE Vernova (GEV) trades at $1,039.90, up 4.95% in the last session, supported by strong technical momentum and bullish analyst sentiment. The company reported mixed Q2 2026 earnings with a miss on EPS expectations but maintains robust revenue growth and a massive $176 billion backlog. Valuation metrics remain elevated with a P/E of 29.01 and EV/EBITDA of 86.33, reflecting high growth expectations tied to AI-driven power demand.
Outlook remains positive given GEV's strategic positioning in AI infrastructure and energy transition, though premium valuation and execution risks on backlog conversion warrant caution. Strong institutional support with 76% buy ratings and consensus price target of $1,270 suggests upside potential, but investors should monitor quarterly execution against high expectations.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →